Is PET-CT Worth — the Extra Cost Over a CT Scan?

Tell your oncologist before substituting one scan for the other. A CT scan is not a lower-cost version of PET-CT — they answer different clinical questions. Swapping without your team's knowledge may delay a staging decision or leave your team working from incomplete information. If cost is the barrier, your oncologist may be able to defer the scan, check scheme eligibility with the imaging centre, or confirm whether CT can answer the current question at this stage of your treatment.

Many group health insurance policies cover PET-CT when it is referred with a clinical indication. The key step is to confirm with the imaging centre whether your insurer is empanelled and whether pre-authorisation is needed before your appointment. Reimbursement policies require you to keep the referral letter, the payment receipt, and the imaging report. Government scheme eligibility depends on the scheme and your enrolment status; the imaging centre or your treating hospital can confirm this for you.

For some clinical questions, yes; for others, CT gives equally useful information at lower cost and lower radiation. PET-CT is more sensitive for detecting metabolically active disease in certain cancers — particularly lymphoma, lung cancer, and head and neck cancers — and for distinguishing viable tumour from post-treatment change. For routine follow-up of a well-characterised cancer where your team is monitoring for size change, CT can be equally informative. Which is more appropriate depends on the question being asked, not on the technology alone.

This depends on your cancer type, your treatment plan, and how your disease is responding. NCCN and ESMO guidance recommends PET-CT at specific points — typically at staging, after a defined number of treatment cycles in certain cancers, and when restaging before surgery. Between those points, CT is the usual monitoring tool for most cancers. Your oncologist will schedule each scan at the point where the result will change a decision, not on a fixed calendar.

You can ask, and it is reasonable to ask your oncologist to explain the choice. They will tell you whether the clinical question at this point genuinely needs PET's metabolic information or whether CT is sufficient. Requesting PET-CT because it feels more thorough does not improve your care if CT answers the question — it adds cost and a higher radiation dose without benefit. If you are uncertain about the overall treatment plan, a second opinion from another oncologist is a more useful step.

It usually means the PET has detected metabolically active tissue that was too small to be characterised clearly on CT, or a site of disease where CT is less reliable. This finding may change your staging, your treatment plan, or both. It does not automatically mean the cancer is more widespread than your team had thought — some PET findings are inflammatory or incidental — and your oncologist will determine whether a biopsy or further imaging is needed to confirm what the scan has found.